Bcl-2 and Aurora Kinase Inhibitor Combination Therapy for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including single-agent targeted therapies, often fail to provide effective solutions for many patients due to resistance and toxicity issues, limiting their clinical benefit.
Innovation Solution
The use of therapeutic combinations of inhibitors, specifically pairing an inhibitor of the Bcl-2 family of proteins with an aurora kinase inhibitor, such as navitoclax with an aurora kinase inhibitor, to treat cancers like breast, ovarian, pancreatic, or prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent targeted therapies are used, then treatment simplicity is maintained, but treatment effectiveness decreases due to resistance and toxicity
Solution Approach 1:
The patent combines two different targeted therapy agents (Bcl-2 family inhibitor and aurora kinase inhibitor) into a single treatment regimen. This merging approach addresses the contradiction by improving treatment effectiveness through synergistic action while maintaining manageable complexity through a standardized combination protocol rather than multiple separate agents.
Solution Approach 2:
The treatment regimen functions as a composite therapeutic system where two distinct molecular mechanisms (Bcl-2 inhibition and aurora kinase inhibition) work together to overcome resistance and enhance efficacy. This composite approach resolves the contradiction by achieving superior treatment effectiveness through integrated action while avoiding the complexity of multi-agent regimens.
2Reliability
If combination therapies are used, then treatment effectiveness improves by overcoming resistance, but therapy complexity increases
Solution Approach 1:
The patent merges two targeted therapy agents into a unified treatment approach that leverages synergistic effects to overcome cancer resistance. This resolving principle improves treatment effectiveness while managing complexity by establishing a clear combination protocol rather than coordinating multiple separate treatment streams.
Solution Approach 2:
The combination therapy exhibits multi-functionality by simultaneously achieving multiple therapeutic goals: overcoming resistance, enhancing response, and reducing toxicity. This universal approach resolves the contradiction by delivering multiple benefits through a single integrated regimen rather than requiring multiple specialized treatments.
3Ease of operation
If single-agent therapies are used, then therapy simplicity is maintained, but toxicity management becomes difficult
Solution Approach 1:
The patent combines two agents with complementary toxicity profiles to achieve a synergistic therapeutic effect while managing harmful factors. The combination approach resolves the contradiction by improving ease of operation through a standardized regimen while effectively managing toxicity through the specific pairing of Bcl-2 and aurora kinase inhibitors.
Data Source
AI summary
The present invention relates to a combination therapy of an inhibitor of the Bel-2 family of proteins selected from navitoclax, venetoclax, A-1331852, AZD5991, or A-1155463, together with an aurora kinase inhibitor for use in a method of treatment of a cancer selected from breast, ovarian, pancreatic, or prostate cancer in a patient.